title: [Efficacy of capecitabine/cisplatin chemotherapy after failure of all conventional therapies in patients with advanced gastric cancer].
abstract: There is no standard therapy for advanced gastric cancer patients who had already failed treatment with major anti-cancer drugs including fluoropyrimidine, cisplatin, taxans, and irinotecan. We report the results of treatment with capecitabine and cisplatin(XP)after the failure of all other conventional therapies. A total of five advanced gastric cancer patients were treated. The median age was 59 years(range, 46-76); there were 3male and 2 female patients; performance status was 0/1/2: 2/2/ 1 patients, respectively. The median duration from start of first-line chemotherapy to XP was 653 days(range, 372-1,107). Three patients were treated after fourth-line therapy and two patients after fifth-line therapy. All of the patients had received S-1, cisplatin, irinotecan, paclitaxel, and docetaxel previously. Patients received 80mg/m2 of cisplatin intravenously on day 1, and 1,000mg/m2 of capecitabine orally twice a day from day 1 to day 14 followed by a 7-day rest period. Treatment courses were between 2 to 5. Median time to progression was 107 days. Median overall survival was 245 days. One PR and one SD were reported. All reported adverse events were manageable. XP is considered one of the effective regimens for advanced gastric cancer after all conventional therapies have failed.
authors.affiliation: Dept. of Surgery, Osaka General Medical Center, Osaka, Japan.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nishikawa
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Iwase
authors.forename: Toyokazu
authors.initials: T
authors.lastname: Aono
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Masaya
authors.initials: M
authors.lastname: Nomura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tamagawa
authors.forename: Chu
authors.initials: C
authors.lastname: Matsuda
authors.forename: Takashi
authors.initials: T
authors.lastname: Deguchi
authors.forename: Junji
authors.initials: J
authors.lastname: Kawada
authors.forename: Shigeyoshi
authors.initials: S
authors.lastname: Higashi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Umeda
authors.forename: Koichi
authors.initials: K
authors.lastname: Deguchi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Fushimi
authors.forename: Mari
authors.initials: M
authors.lastname: Takagi
authors.forename: Akiko
authors.initials: A
authors.lastname: Fukui
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tanaka
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D003841:Deoxycytidine; D000069287:Capecitabine; D002945:Cisplatin; D005472:Fluorouracil